3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
16
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Lung Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Multiple Myeloma
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Neuroendocrine Tumors
3
Neoplasm Metastasis
3
Lymphoma, Large B-Cell, Diffuse
3
Anus Neoplasms
3
Testicular Neoplasms
2
Solid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Laryngeal Neoplasms
2
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Fluorodeoxyglucose F18
×
1 year
×
Clear all
No trials found.